| abstract |
The present invention relates to methods for treating cancer in a patient comprising administering an anti-PD-1 antibody or antigen binding fragment thereof in specific amounts to the patient about every six weeks, in combination with administering an anti-CTLA4 antibody to the patient about every six weeks. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and a dosage of an anti-CTLA4 antibody or antigen-binding fragment thereof, and uses thereof for treating cancer. |